Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 657.80

+1.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tom pope who wrote (1005)	10/30/2005 10:55:58 PM
From: Miljenko Zuanic	Read Replies (2) of 3557

IF AACR-EORTC abstracts are available (to selected ones) than maybe there is something new from PI. Second is that EU two combination trials are progressing well??? The best idea will be from expenditure in 3Q? Going forward REGN/Sanofi will need well define and fully GMP manufacturing process for Trap, as it will be (for now on) used for efficacy study. So, process can not change in PIII or later on (without bioequivalence study). Start of any PII will depend on this issue. Maybe, Sanofi decided to go against Avastin (head to head) in PII. Yes, right! In 2008. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next